Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status
      Google Scholar   
Citation:
Ann Oncol vol 25 (suppl 4)
Meeting Instance:
ESMO 2014
Year:
2014
Type:
Abstract
Sub type:
Published Only
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2247  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                                         
Networks:
LAPS-MD017, LAPS-MN026, LAPS-NY016, PR028   
Study
NCCTG-N063D
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: